Clinical Trials News

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance Contract...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in people with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC). The study m...

BOSTON & STAFFORDSHIRE, England--(BUSINESS WIRE)--Instem announces a 5-year extension of its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA)....

ZURICH--(BUSINESS WIRE)--AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the presentation of new clinical data from the global Phase 2 clinical trial (AP-101-02) evaluating the company’s lead program, AP-101, in patients with ALS. AP-101 is an investigational human-derived antibody directed against misfolded superoxide dismutase 1 (SOD1). AP-101 is...

RALEIGH, N.C.--(BUSINESS WIRE)--On February 13, 2026, QHP Capital, L.P. (“QHP”) announced the closing of a $1.1 Billion single-asset continuation vehicle for Azurity Pharmaceuticals, Inc. (“Azurity”). The transaction provides liquidity to existing limited partners while enabling QHP to maintain control and continue executing on Azurity’s long-term value creation plan. The transaction was led by HarbourVest Partners, LLC (“HarbourVest”), with Pantheon Ventures, L.P. participating as a significan...

NEW YORK--(BUSINESS WIRE)--Sunrise Group, a pioneer in medical device innovation and sleep care, today announced results from the SUNSAS clinical study, now published in The Lancet Regional Health – Europe, a leading international medical journal. Supported by the French Ministry of Health through the Forfait Innovation program, this study is the largest randomized controlled trial to date evaluating an at-home diagnostic pathway for obstructive sleep apnea (OSA) compared with gold-standard pol...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Crossbow announced it raised $77 million in a Series B financing that will advance the development of TCR-mimetic antibody therapies to treat cancer....

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting April 17-22 in San Diego....

SHANGHAI, China--(BUSINESS WIRE)--Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Generation T-Cell Engager Therapies...

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced the publication of preclinical research evaluating Pressure-Enabled Drug Delivery™ (PEDD™) of nelitolimod in liver tumor models in Frontiers in Oncology. The study evaluated the delivery and biologic activity...